EMBRACA: What the Breast Cancer Trial Found

A pill instead of an infusion

BRCA1 and BRCA2 are repair genes. When a cell inherits a broken copy and the working copy fails, one of its main ways of mending broken DNA is gone. PARP inhibitors block a different repair route, and cancer cells that have lost the first one cannot cope without the second.

Talazoparib is one of those drugs: one tablet, once a day, taken at home. EMBRACA compared it with chemotherapy in people whose advanced breast cancer carried an inherited BRCA mutation.

Who could join, and what the comparison was

Field	Detail
Trial	EMBRACA
Identifier	NCT01945775
Phase	Phase 3
Design	Randomised 2:1, open-label
Cancer type	Advanced HER2-negative breast cancer with an inherited BRCA1 or BRCA2 mutation
Comparator	Talazoparib 1 mg daily, against the physician's choice of capecitabine, eribulin, gemcitabine or vinorelbine
Primary endpoint	Progression-free survival, assessed by blinded independent central review

The trial's dosing is recorded here for the sake of the record. If you are on talazoparib, the amount on your own prescription label is the one that counts.

431 people were randomised: 287 to talazoparib and 144 to chemotherapy. The mutation had to be inherited — a germline BRCA change — not one acquired by the tumour alone.

Three months, and a much higher response rate

Median progression-free survival was 8.6 months with talazoparib and 5.6 months with chemotherapy, a hazard ratio of 0.54 (95% CI 0.41 to 0.71, p<0.001).

Tumours shrank in 62.6% of the talazoparib group against 27.2% of the chemotherapy group — an odds ratio of 5.0 (95% CI 2.9 to 8.8, p<0.001). More than twice as many people saw their cancer visibly retreat.

Severe blood-count problems, mainly anaemia, were more common with talazoparib: 55% against 38%. Severe non-blood side effects were slightly less common: 32% against 38%.

What patients reported

The trial collected patient-reported outcomes, and they favoured talazoparib. Global health status and quality of life improved significantly, and the time until a clinically meaningful worsening of either that measure or breast symptoms was significantly longer.

Extended follow-up in 2020 confirmed both of those findings. For a treatment measured in months, how those months feel is a substantial part of the answer.

The final survival analysis found no difference

By the September 2019 cutoff, 216 people on talazoparib (75.3%) and 108 on chemotherapy (75.0%) had died. Median follow-up was 44.9 and 36.8 months.

Median survival was 19.3 months with talazoparib (95% CI 16.6 to 22.5) and 19.5 months with chemotherapy (95% CI 17.4 to 22.4). The hazard ratio was 0.848 (95% CI 0.670 to 1.073, p=0.17).

One complication: most people went on to other treatments afterwards. 32.6% of the chemotherapy group later received a PARP inhibitor, against 4.5% of the talazoparib group. After statistical adjustment for later PARP inhibitor and platinum use, the hazard ratio was 0.756 (95% bootstrap CI 0.503 to 1.029) — still not a demonstrated difference.

Severe side effects across the full follow-up were 69.6% with talazoparib and 64.3% with chemotherapy.

What this trial cannot tell you

• Whether talazoparib helps people live longer. The final analysis says it did not, and the adjusted analysis did not change that.
• Whether it applies without an inherited BRCA mutation. Only germline BRCA1 and BRCA2 carriers were eligible.
• Whether it is the best PARP inhibitor. The comparison was against chemotherapy, not another drug of the same class.
• What the open-label design cost in precision. Everyone knew whether they were taking a pill or having an infusion, and quality-of-life scores are reported by the patient.

Questions about a BRCA result in breast cancer

• Was my BRCA change inherited, or found only in the tumour?
• If this buys time rather than years, what does that change for me?
• What would you monitor for anaemia, and how often?

Sources

This article was written from the sources below, which were checked on the source-check date shown above.

• NEJM: Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation (EMBRACA) (primary)
• Annals of Oncology: Final Overall Survival Results from EMBRACA (primary)

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.